First human test of new drug for Alzheimer's risk in down syndrome halted early
NCT ID NCT06673069
Summary
This early-stage study aimed to check the safety and how the body processes a new drug called ION269 in adults with Down syndrome who have brain amyloid, a protein linked to Alzheimer's disease. Only one person was enrolled before the study was stopped. The main goal was to see if the drug was safe and to measure its levels in the blood and spinal fluid.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ionis Investigative Site
Indianapolis, Indiana, 46202, United States
-
Ionis Investigative Site
Kansas City, Kansas, 66205, United States
-
Ionis Investigative Site
Lexington, Kentucky, 40536, United States
-
Ionis Investigative Site
St Louis, Missouri, 63110, United States
-
Ionis Investigative Site
Madison, Wisconsin, 53705, United States
-
Ionis Investigative Site
Barcelona, 08041, Spain
Conditions
Explore the condition pages connected to this study.